
Annual report 2024
added 03-07-2026
Evogene Ltd. Net Debt 2011-2026 | EVGN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Evogene Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -3.44 M | -3.24 M | -10.2 M | -5.21 M | -95.5 M | -24.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.24 M | -95.5 M | -23.6 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.79 | -1.15 % | $ 4.31 M | ||
|
argenx SE
ARGX
|
-89.9 M | $ 700.45 | -1.19 % | $ 25 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.6 | 1.41 % | $ 8.66 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Grifols, S.A.
GRFS
|
5.36 B | $ 7.81 | -2.01 % | $ 6.83 B | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 225.98 | -1.32 % | $ 5 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
ADC Therapeutics SA
ADCT
|
-459 M | $ 4.13 | -5.06 % | $ 105 M | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.49 | 0.58 % | $ 1.04 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
BioCardia
BCDA
|
212 K | $ 1.26 | -0.79 % | $ 26.7 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 91.19 | 1.21 % | $ 27.2 B | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 14.2 | -0.7 % | $ 208 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 6.68 | -4.57 % | $ 183 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 7.92 | 1.67 % | $ 1.31 B | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.54 | -5.22 % | $ 16 M | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.44 | -1.37 % | $ 367 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-48 M | - | - | $ 521 M | ||
|
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.6 | -4.0 % | $ 7.83 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | ||
|
Actinium Pharmaceuticals
ATNM
|
-72.3 M | $ 1.11 | -1.77 % | $ 33.4 M |